-

UnitedHealth Group Donates $5 Million to Support National Program to Develop Convalescent Plasma Treatments for COVID-19

  • Funding will support federally sponsored national Convalescent Plasma Expanded Access Program being led by Mayo Clinic
  • Program will speed collection and increase availability of treatments derived from antibodies collected from recovered COVID-19 patients that may help others fight the virus and improve survivorship
  • Donation brings to nearly $70 million UnitedHealth Group’s initial commitment to fight COVID-19 and support impacted communities

MINNETONKA, Minn.--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) will donate $5 million to support a federally sponsored program aimed at accelerating and expanding the availability of investigational convalescent plasma treatments for COVID-19 patients nationwide. The initiative, led by Mayo Clinic, coordinates efforts to collect plasma from donors who have recovered from COVID-19 and distribute it to hospitalized patients with severe or life-threatening COVID-19 infections.

“Developing therapeutics and effective treatments for COVID-19 is essential to our efforts to fight this pandemic,” said Dr. Richard Migliori, executive vice president of Medical Affairs and chief medical officer for UnitedHealth Group. “Treating patients with convalescent plasma has the potential to save many lives and we’re honored to collaborate with Mayo Clinic and support this promising research.”

Mayo Clinic is coordinating efforts across more than 1,600 sites in all 50 states, the District of Columbia and Puerto Rico to collect blood plasma from recovered COVID-19 donors who meet several criteria established by the FDA. To date, more than 600 patients have received convalescent plasma treatments with more being included in the study every day. Physicians at any institution treating hospitalized patients with COVID-19 can participate by visiting uscovidplasma.org.

“We’re collaborating with health care organizations across the country to develop new treatments, prevent COVID-19 and address hotspots that overburden the health care system,” said Dr. Michael Joyner at Mayo Clinic, who is leading the effort. “Early indications show that convalescent plasma treatments could help in all of these areas and we greatly appreciate UnitedHealth Group’s support to advance this critical science.”

The donation brings to nearly $70 million UnitedHealth Group’s initial commitment to fight COVID-19 and support impacted communities including:

  • $30 million in efforts, including $5 million from the United Health Foundation, to protect and support health care workers.
  • $10 million from the United Health Foundation to support states where COVID-19 is having an outsized impact.
  • $10 million to support COVID-19 response outside of the United States.
  • $5 million from the United Health Foundation to support seniors.
  • $5 million from the United Health Foundation to provide care and support for people experiencing food insecurity or homelessness.
  • $3 million to transition company cafeterias and staff to prepare more than 75,000 free meals for local communities each week.

About UnitedHealth Group

UnitedHealth Group (NYSE: UNH) is a diversified health care company dedicated to helping people live healthier lives and helping to make the health system work better for everyone. UnitedHealth Group offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services. For more information, visit UnitedHealth Group at www.unitedhealthgroup.com or follow @UnitedHealthGrp on Twitter.

Contacts

Eric Hausman
952-936-3963
Eric.Hausman@uhg.com

UnitedHealth Group

NYSE:UNH

Release Versions

Contacts

Eric Hausman
952-936-3963
Eric.Hausman@uhg.com

More News From UnitedHealth Group

Scott Gottlieb, M.D., Joins UnitedHealth Group Board of Directors

--(BUSINESS WIRE)--Dr. Scott Gottlieb, former U.S. Food and Drug Administration (FDA) commissioner, is joining UnitedHealth Group’s (NYSE: UNH) Board of Directors, effective immediately. Dr. Gottlieb, 53, served as FDA commissioner from 2017 to 2019, where he became known for promoting transparency, strengthening patient safety and widening consumer choice. He led initiatives to modernize regulations to help foster medical innovation, promote competition in the pharmaceutical market, confront t...

UnitedHealth Group Recommends Shareholders Reject "Mini-Tender" Offer by Tutanota

--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced that it recently became aware of an unsolicited “mini-tender” offer by Tutanota LLC (Tutanota) to purchase up to 175,000 shares of UnitedHealth Group’s common stock, representing significantly less than 1% of UnitedHealth Group’s common stock outstanding. The offer price of $325.00 per share is conditioned on, among other things, the closing price per share of UnitedHealth Group’s common stock exceeding $325.00 per share on the l...

UnitedHealth Group Announces Leadership Transition

--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced the appointment of Stephen J. Hemsley as its chief executive officer, effective immediately, following Andrew Witty’s decision to step down as CEO for personal reasons. Hemsley, who served as company CEO from 2006-2017, will remain chairman of the company’s Board of Directors and Witty will serve as a senior adviser to Hemsley. “We are grateful for Andrew’s stewardship of UnitedHealth Group, especially during some of the most cha...
Back to Newsroom